



## Newron Pharmaceuticals to Participate in a Fireside Chat at the 37<sup>th</sup> Annual ROTH Conference

**Milan, Italy and Morristown, NJ, USA – March 11, 2025** – [Newron Pharmaceuticals S.p.A.](#) (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will participate in a fireside chat at the 37<sup>th</sup> Annual ROTH Conference on Monday, March 17 at 11:30 a.m. PDT.

A live audio webcast of the fireside chat can be accessed on ROTH Conference website [here](#).

### **About Newron Pharmaceuticals**

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system.

Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available first- and second-generation antipsychotic medications.

Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson’s disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: [www.newron.com/](http://www.newron.com/)

### **For more information, please contact:**

#### **Newron**

Stefan Weber – CEO  
+39 02 6103 46 26  
[pr@newron.com](mailto:pr@newron.com)

#### **UK/Europa**

Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting  
+44 20 3727 1000  
[SCnewron@fticonsulting.com](mailto:SCnewron@fticonsulting.com)

#### **Switzerland**

Valentin Handschin, IRF  
+41 43 244 81 54  
[handschin@irf-reputation.ch](mailto:handschin@irf-reputation.ch)

#### **Germany/Europa**

Anne Hennecke / Maximilian Schur, MC Services  
+49 211 52925227  
[newron@mc-services.eu](mailto:newron@mc-services.eu)

#### **USA**

Paul Sagan, LaVoieHealthScience  
+1 617 374 8800, Ext. 112  
[psagan@lavoiehealthscience.com](mailto:psagan@lavoiehealthscience.com)

###